Obiltoxaximab

Identification

Summary

Obiltoxaximab is a monoclonal antibody used for prophylaxis or treatment of inhalational anthrax.

Brand Names
Anthim
Generic Name
Obiltoxaximab
DrugBank Accession Number
DB05336
Background

Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin. Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa.

Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
148000.0 Da
Sequences
Not Available
Synonyms
  • Obiltoxaximab
External IDs
  • ETI-204

Pharmacology

Indication

Investigated for use/treatment in anthrax exposure, bacterial infection, crohn's disease, and graft versus host disease.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofInhalational anthrax••••••••••••
Prophylaxis ofInhalational anthrax••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

ETI-204 is an affinity-enhanced, de-immunized antibody, which means that its ability to bind to its target pathogen has been strengthened and that elements that might cause an immune response have been removed. ETI-204 targets and binds to Protective Antigen, which prevents the anthrax toxins from binding to and entering the cells in the body, thereby preventing death.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Obiltoxaximab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Obiltoxaximab.
AducanumabThe risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Aducanumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Obiltoxaximab.
AlirocumabThe risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Alirocumab.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
AnthimSolution100 mg / mLIntravenousElusys Therapeutics, Inc.2022-09-13Not applicableCanada flag
AnthimSolution100 mg/1mLIntravenousElusys Therapeutics, Inc.2016-03-18Not applicableUS flag
Obiltoxaximab SflInjection, solution, concentrate100 mg/mlIntravenousSfl Pharmaceuticals Deutschland Gmb H2020-12-23Not applicableEU flag

Categories

ATC Codes
J06BC04 — Obiltoxaximab
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
29Z5DNL48C
CAS number
1351337-07-9

References

General References
  1. Mohamed N, Clagett M, Li J, Jones S, Pincus S, D'Alia G, Nardone L, Babin M, Spitalny G, Casey L: A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun. 2005 Feb;73(2):795-802. [Article]
PubChem Substance
347910089
RxNav
1746906
Wikipedia
Obiltoxaximab
FDA label
Download (315 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Not Yet RecruitingTreatmentAnthrax / Bacterial Infections1
1CompletedOtherInhalational Anthrax4
1CompletedTreatmentAnthrax1
1CompletedTreatmentBacillus Anthracis (Anthrax)1
1CompletedTreatmentHealthy Volunteers (HV)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionIntravenous100 mg / mL
SolutionIntravenous100 mg/1mL
Injection, solution, concentrateIntravenous100 MG/ML
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Drug created at November 18, 2007 18:23 / Updated at April 30, 2021 13:06